Advertisement
New Zealand markets closed

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NZD/USD

    0.5892
    -0.0013 (-0.22%)
     

  • NZD/EUR

    0.5523
    -0.0022 (-0.39%)
     

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD

    2,406.70
    +8.70 (+0.36%)
     

  • NASDAQ

    17,037.65
    -356.67 (-2.05%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • Dow Jones

    37,986.40
    +211.02 (+0.56%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • NZD/JPY

    91.0710
    -0.1830 (-0.20%)
     

Vocal Biomarker Market to Surpass US$ 9.1 Billion by 2033 as Prevalence of Parkinson's Disease and Depression Surges: Fact.MR

FACT.MR
Updated ·5-min read
FACT.MR
FACT.MR

Key Companies to Invest in Audio-based Diagnostic Systems, Notably Vocal Biomarkers to Help Quickly Detect Language-related Issues

Rockville, Jan. 31, 2023 (GLOBE NEWSWIRE) -- The global vocal biomarker market is anticipated to be valued at US$ 2.3 billion in 2023. It is projected to exceed US$ 9.1 billion by 2033. Over the forthcoming decade (2023 to 2033), the global demand for vocal biomarkers is projected to develop at a CAGR of 14.7%.

The market for vocal biomarkers is expected to rise significantly over the next ten years. This may be attributed to the rising incidence of brain, psychiatric, and other language-related illnesses.

ADVERTISEMENT

Surging prevalence of Parkinson's disease, depression, cardiovascular disease, and attention deficit disorders worldwide would propel demand. Vocal biomarkers are expected to witness increasing demand as less invasive diagnostic methods are needed to treat these diseases.

Download Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=719


Report Attributes

             Details

Historical Data

2023 - 2032

Value Projection (2032)

   US$ 11 Billion

Growth Rate (2022-2032)

14.7 % CAGR

No. of Pages

170 pages

No. of Tables

141 Tables

No. of Figures

105 Figures


Key Takeaways:

  • By indication, the cardiovascular disorders segment is projected to hold lion’s share in the vocal biomarker market by 2033.

  • Neurological disorders are expected to remain at the second position in terms of share, followed by cardiovascular disorders.

  • The USA vocal biomarker market is set to showcase an astonishing share with increasing prevalence of Parkinson’s disease.

  • In Asia Pacific, Japan is estimated to surge at a fast pace throughout the forecast period.

  • Korea vocal biomarker market is expected to create new opportunities in the next ten years amid high investments in healthcare infrastructure.

Growth Drivers:

  • Increasing use of vocal biomarkers for detecting illnesses by utilizing speech features in a non-invasive method is likely to aid sales.

  • Surging investments by the pharmaceutical industry worldwide to come up with new vocal biomarkers for supporting early diagnosis of Alzheimer’s would push demand.

Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=719

Competitive Landscape:

As per the study, Boston Technology Corporation, EVOCAL Health, Audio Profiling, Cogito Corporation, and Kintsugi are considered to be a few leading players in the vocal biomarker market. Given the presence of key players, the market is projected to be highly fragmented. Acquisitions and mergers are expected to be key strategies for renowned players to gain a competitive edge in the market.

Manufacturers are acquiring and investing in businesses that specialize in research activities to develop new technologies. A few players are looking to develop and launch innovative products to gain a competitive advantage in the market.

For instance,

  • In August 2022, PureTech Health plc announced that its founding company, Sonde Health has entered into a multi-year agreement with pharmaceutical company Koye Pharmaceuticals. This agreement will help the company to develop novel voice biomarker detection and monitoring capabilities for chronic obstructive pulmonary disease (COPD) in India.

  • In August 2022, Ellipsis Health and Ceras Health, a leading digital health solutions company, joined hands to accelerate the former’s discovery in using the human voice as a mental biomarker.

Key Companies Profiled by Fact.MR

  • Boston Technology Corporation

  • EVOCAL Health

  • Audio Profiling

  • Cogito Corporation

  • Kintsugi

  • Sharecare Inc.

  • Microtest Health

  • Sonde Health

  • AudEERING

  • Beyond Verbal

  • IBM Corporation

Get Full Access of Complete Report:
https://www.factmr.com/checkout/719

More Valuable Insights on Vocal Biomarker Market

With the modern study, Fact.MR provides an unbiased analysis of the global vocal biomarker market over the forecast period (2023 to 2033). The study also provides a comprehensive analysis of key trends, opportunities, and drivers driving the sales of vocal biomarkers through detailed segmentation as follows:

Technique:

  • Frequency

  • Amplitude

  • Error Rate

  • Vocal Rise or Fall Time

  • Phonation Time

  • Vocal Tremor

  • Pitch

  • Others

Indication:

  • Psychiatric Disorders

  • Respiratory Disorders

  • Cardiovascular Disorders

  • Traumatic Brain Injury (TBI)

  • Neurological disorders

  • Other

End User:

  • Hospitals & Clinics

  • Contract Research Organizations CROs)

  • Academic & Research Centers

  • Other End Users

Region:

  • North America

  • Latin America

  • Europe

  • Asia and Pacific

  • The Middle East and Africa

Key Questions Covered in the Vocal Biomarker Market Report

  • How will the demand for vocal biomarkers surge during the forecast period?

  • Which are the key trends propelling the sales of a vocal biomarker in the market?

  • Which region will be the most lucrative in the vocal biomarker market from 2023 to 2033?

  • What is the projected market valuation of the vocal biomarker market in 2033?

  • What are the challenges vocal biomarker providers might face over the upcoming decade?

  • Which will be the leading end users in the vocal biomarker market?

Explore Fact. MR’s Coverage in the Healthcare Domain

Cancer Biomarkers Market: The cancer biomarker market is anticipated to exceed US$ 34 billion by 2032 from US$ 11 billion in 2022. During the forecast period, the global cancer biomarkers market is set to propagate to a staggering 12% CAGR.

Biomarker Detection Systems Market: Validation of biomarkers is a time-consuming process. This makes biomarker industries receive low-cost benefits. Also, the availability of cheap alternatives to biomarkers act as a hindrance to the growth of biomarker detection systems.

Tuberculosis Biomarkers Market: Prevalence and mortality of multidrug-resistant tuberculosis worldwide would create a strong need for tuberculosis biomarkers. Increasing use of biomarkers in modified medicine and drug discovery & development are key trends driving the market.

High-Sensitivity Cardiac Biomarker Market: The global high-sensitivity cardiac biomarker market is projected to develop as the number of cardiac specialty hospitals and clinics increases in various regions. It is anticipated to unswervingly boost the high-sensitivity cardiac biomarker market.

About Fact.MR

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client’s satisfaction.

Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Connect to Analyst: Mr. Shambhu Nath Jha
Email : shambhu@factmr.com
Sales Team : sales@factmr.com
Follow Us: LinkedIn | Twitter | YouTube